The Growing Importance of Polypills in the Management of Cardiovascular Diseases

Overview : By Jose Maria Castellano, MD* The worldwide epidemic of cardiovascular disease sparked nearly 15 years ago the concept of a CV polypill. It seems counterintuitive that in the time of personalized medicine, a cardiovascular polypill would be deemed as one... more

Myocardial infarction with non-obstructive coronary arteries (MINOCA)

Overview : By Professor Stefan Agewall A sizeable proportion of MIs, ranging between 1% and 14%, occur in the absence of obstructive coronary artery disease. The diagnostic criteria of MINOCA fulfill the universal criteria of myocardial infarction, but without coronary artery stenosis... more

Novel lipid lowering therapy against coronary atherosclerosis: role of PCSK9 inhibitors

Overview : By Professor ​Masayuki Yoshida​ ​Statins have been the first choice option to prevent cardiovascular disease (CVD). However, because of insufficient efficacy in certain groups of high risk patients, such as familial hypercholesterolemia (FH), considerable interest exists in the search for... more

Bleeding Prevention and Treatment

Overview : By Dr Martínez Selles The assessment of any kind of bleeding event in a NOACs patient is quite different from an AVK (antivitamin-K) dependent patient. There are questions to take into consideration, such as the onset, the severity and the... more

Improving persistence and clinical results of drug therapy: the role of a polypill

Overview : By Dr José María Castellano In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical... more

Chest pain in aortic stenosis: novel diagnostic and therapeutic data

Overview : By Dennis Cokkinos Angina pectoris (AP) in aortic stenosis (AS) is not unusual. It can be seen in up to 75% of patients. It is associated with coronary artery disease (CAD) in 50-74% of patients; it’s for diagnosing CAD sensitivity... more

Rivaroxaban not FDA approved for the risk reduction of secondary CV events in patients with ACS

Overview : By Professor Juan Tamargo The FDA's Cardiovascular and Renal Drugs Advisory Committee declined to approve (6-4, with one abstention) to approve rivaroxaban for use in acute coronary syndromes (ACS). Despite positive results from the global, phase III ATLAS ACS 2-TIMI... more

Ticagrelor Added to Recommended Agents for MI

Overview : By Professor Juan Tamargo, Madrid, Spain The new update of the guideline for the management of patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) of the the American Heart Association and the American College of Cardiology Foundation recommended prasugrel,... more

The first approved gene therapy product in a Western country

Overview : By Professor Juan Tamargo, Madrid, Spain The agency's Committee for Medicinal Products for Human Use (CHMP) of The European Medicines Agency (EMA) has for the first time recommended recommended the authorization under "exceptional circumstances" for alipogene tiparvovec, an "orphan medicine"... more

The EMA is planning to review the use of aliskiren-containing medicines

Overview : By Professor Juan Tamargo, Madrid, Spain The European Medicines Agency is planning to review the use of aliskiren-containing medicines after the ALTITUDE trial, which was terminated prematurely, found no apparent benefit among patients randomized to aliskiren (Rasilez in the EU/Tekturna... more

Page: